Treatment of palmoplantar psoriasis with oral roflumilast: a case series

被引：0
|
作者：
Lasheras-Perez, Miguel Antonio [1 ,2 ]
Penuelas-Leal, Rodrigo [3 ]
Sanchez-Carazo, Jose Luis [3 ]
Sahuquillo-Torralba, Antonio Javier [1 ,2 ]
Magdaleno-Tapial, Jorge [3 ]
Torres-Navarro, Ignacio [1 ,2 ]
Unamuno-Bustos, Blanca [1 ,2 ]
Lopez-Davia, Javier [1 ,2 ]
Pujol-Marco, Conrad [1 ,2 ]
Escutia-Munoz, Begona [1 ,2 ]
Botella-Estrada, Rafael [1 ,2 ,4 ]
机构：
[1] La Fe Univ & Polytech Hosp, Dept Dermatol, Valencia, Spain
[2] Hlth Res Inst Hosp, La Valencia, Spain
[3] Valencia Gen Hosp, Dept Dermatol, Valencia, Spain
[4] Univ Valencia, Dept Dermatol, Valencia, Spain
来源：
CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2024年
关键词：
D O I：
10.1093/ced/llae229
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Palmoplantar psoriasis (PP) is a particular type of psoriasis that can justify systemic treatment. Roflumilast is a targeted inhibitor of phosphodiesterase-4 that has been recently approved by the US Food and Drugs Administration as a cream for the treatment of plaque psoriasis. In a small randomized clinical trial and single case reports, oral roflumilast has demonstrated efficacy in the treatment of plaque psoriasis. To the best of our knowledge, we present the first case series of patients with PP treated with oral roflumilast.
引用
收藏
页数：3
相关论文
共 50 条
12345